Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatomyositis | 31 | 2024 | 258 | 12.140 |
Why?
|
Lupus Erythematosus, Discoid | 12 | 2024 | 61 | 4.250 |
Why?
|
Fasciitis | 7 | 2023 | 67 | 4.210 |
Why?
|
Eosinophilia | 8 | 2023 | 560 | 3.840 |
Why?
|
Connective Tissue Diseases | 6 | 2024 | 285 | 2.480 |
Why?
|
Lupus Erythematosus, Cutaneous | 9 | 2021 | 73 | 2.390 |
Why?
|
Lupus Erythematosus, Systemic | 12 | 2024 | 2155 | 2.040 |
Why?
|
Dermatologic Agents | 10 | 2024 | 313 | 1.970 |
Why?
|
Mycophenolic Acid | 5 | 2022 | 348 | 1.910 |
Why?
|
Raynaud Disease | 4 | 2023 | 79 | 1.810 |
Why?
|
Scleroderma, Systemic | 6 | 2023 | 344 | 1.740 |
Why?
|
Immunoglobulins, Intravenous | 8 | 2023 | 664 | 1.710 |
Why?
|
Skin Diseases | 9 | 2022 | 1094 | 1.650 |
Why?
|
Skin Ulcer | 3 | 2023 | 130 | 1.410 |
Why?
|
Scleroderma, Localized | 5 | 2023 | 87 | 1.390 |
Why?
|
Dermatology | 11 | 2022 | 918 | 1.390 |
Why?
|
Autoantibodies | 6 | 2024 | 2116 | 1.380 |
Why?
|
Pityriasis Rubra Pilaris | 3 | 2021 | 20 | 1.280 |
Why?
|
Methotrexate | 12 | 2024 | 1719 | 1.260 |
Why?
|
Botulinum Toxins, Type A | 2 | 2023 | 237 | 1.260 |
Why?
|
Hand Dermatoses | 4 | 2016 | 62 | 1.260 |
Why?
|
Exanthema | 4 | 2023 | 503 | 1.240 |
Why?
|
Paraproteinemias | 3 | 2021 | 248 | 1.170 |
Why?
|
Immunosuppressive Agents | 12 | 2024 | 4174 | 1.100 |
Why?
|
Immunologic Factors | 5 | 2021 | 1589 | 0.870 |
Why?
|
Psoriasis | 9 | 2024 | 950 | 0.850 |
Why?
|
Pemphigoid, Bullous | 2 | 2015 | 112 | 0.820 |
Why?
|
Panniculitis | 2 | 2012 | 45 | 0.800 |
Why?
|
Calcinosis | 3 | 2018 | 1469 | 0.770 |
Why?
|
Porphyria Cutanea Tarda | 1 | 2021 | 11 | 0.750 |
Why?
|
Autoimmune Diseases | 3 | 2024 | 2244 | 0.730 |
Why?
|
Adrenal Cortex Hormones | 5 | 2021 | 1880 | 0.720 |
Why?
|
Antimalarials | 4 | 2020 | 907 | 0.700 |
Why?
|
Thiosulfates | 2 | 2018 | 53 | 0.690 |
Why?
|
Skin | 10 | 2024 | 4484 | 0.690 |
Why?
|
Insurance | 1 | 2021 | 113 | 0.650 |
Why?
|
Alopecia Areata | 1 | 2021 | 128 | 0.610 |
Why?
|
Foot Dermatoses | 2 | 2016 | 47 | 0.610 |
Why?
|
Drug Therapy | 1 | 2021 | 503 | 0.600 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2019 | 423 | 0.600 |
Why?
|
Anti-Asthmatic Agents | 1 | 2023 | 574 | 0.600 |
Why?
|
Piperidines | 4 | 2021 | 1656 | 0.600 |
Why?
|
Humans | 133 | 2024 | 761504 | 0.590 |
Why?
|
Sunlight | 2 | 2020 | 337 | 0.550 |
Why?
|
Tumor Necrosis Factor-alpha | 7 | 2021 | 4352 | 0.540 |
Why?
|
Skin Diseases, Genetic | 1 | 2016 | 49 | 0.530 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 646 | 0.520 |
Why?
|
Needlestick Injuries | 1 | 2016 | 71 | 0.520 |
Why?
|
Hidradenitis Suppurativa | 2 | 2018 | 178 | 0.510 |
Why?
|
Erythromelalgia | 1 | 2014 | 15 | 0.480 |
Why?
|
Scleredema Adultorum | 1 | 2014 | 2 | 0.480 |
Why?
|
Tetracycline | 1 | 2015 | 216 | 0.480 |
Why?
|
Rosacea | 1 | 2015 | 59 | 0.470 |
Why?
|
Enchondromatosis | 1 | 2014 | 14 | 0.470 |
Why?
|
Pyrroles | 2 | 2021 | 1125 | 0.460 |
Why?
|
Administration, Cutaneous | 3 | 2024 | 713 | 0.460 |
Why?
|
Facial Dermatoses | 1 | 2014 | 86 | 0.460 |
Why?
|
Contracture | 1 | 2016 | 235 | 0.460 |
Why?
|
Urban Health Services | 1 | 2015 | 177 | 0.450 |
Why?
|
Thalidomide | 2 | 2016 | 885 | 0.440 |
Why?
|
Epidermolysis Bullosa Acquisita | 1 | 2013 | 15 | 0.440 |
Why?
|
Subcutaneous Tissue | 2 | 2020 | 132 | 0.430 |
Why?
|
Quality of Life | 7 | 2023 | 13367 | 0.420 |
Why?
|
Scalp Dermatoses | 1 | 2013 | 44 | 0.410 |
Why?
|
Photography | 1 | 2016 | 532 | 0.410 |
Why?
|
Pyrimidines | 4 | 2021 | 3028 | 0.410 |
Why?
|
Pelvic Neoplasms | 1 | 2014 | 247 | 0.400 |
Why?
|
Patient Preference | 1 | 2019 | 924 | 0.400 |
Why?
|
Severity of Illness Index | 13 | 2024 | 15842 | 0.390 |
Why?
|
Skin Neoplasms | 6 | 2015 | 5821 | 0.390 |
Why?
|
Chondrosarcoma | 1 | 2014 | 296 | 0.390 |
Why?
|
Facial Hemiatrophy | 2 | 2022 | 24 | 0.380 |
Why?
|
Tacrolimus | 1 | 2015 | 733 | 0.380 |
Why?
|
Skin Diseases, Vascular | 1 | 2011 | 41 | 0.370 |
Why?
|
Female | 66 | 2024 | 392644 | 0.370 |
Why?
|
Retrospective Studies | 30 | 2023 | 80636 | 0.360 |
Why?
|
Treatment Outcome | 22 | 2023 | 64680 | 0.360 |
Why?
|
Middle Aged | 41 | 2024 | 220895 | 0.360 |
Why?
|
Radiation Injuries | 2 | 2016 | 1189 | 0.340 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1866 | 0.340 |
Why?
|
Lymphoma, T-Cell | 1 | 2012 | 304 | 0.340 |
Why?
|
Hydroxychloroquine | 4 | 2020 | 426 | 0.340 |
Why?
|
Calciphylaxis | 1 | 2011 | 130 | 0.330 |
Why?
|
Myositis | 2 | 2023 | 271 | 0.330 |
Why?
|
Graft vs Host Disease | 1 | 2022 | 3029 | 0.330 |
Why?
|
Administration, Oral | 4 | 2020 | 4021 | 0.320 |
Why?
|
Immunity, Cellular | 1 | 2015 | 1560 | 0.320 |
Why?
|
Antirheumatic Agents | 2 | 2020 | 1372 | 0.310 |
Why?
|
Edema | 1 | 2012 | 766 | 0.300 |
Why?
|
Panniculitis, Lupus Erythematosus | 2 | 2020 | 5 | 0.300 |
Why?
|
Health Expenditures | 2 | 2022 | 2366 | 0.300 |
Why?
|
Clinical Clerkship | 1 | 2014 | 564 | 0.290 |
Why?
|
Abdominal Pain | 1 | 2014 | 1071 | 0.290 |
Why?
|
Carcinoma, Basal Cell | 2 | 2014 | 560 | 0.290 |
Why?
|
Academic Medical Centers | 4 | 2021 | 2759 | 0.290 |
Why?
|
Adult | 38 | 2024 | 221177 | 0.280 |
Why?
|
Interferon Type I | 2 | 2024 | 562 | 0.280 |
Why?
|
Male | 47 | 2024 | 360804 | 0.280 |
Why?
|
Salvage Therapy | 1 | 2013 | 1264 | 0.280 |
Why?
|
Sunscreening Agents | 2 | 2020 | 139 | 0.270 |
Why?
|
Alopecia | 3 | 2019 | 412 | 0.270 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2013 | 1085 | 0.260 |
Why?
|
Erythema | 2 | 2020 | 262 | 0.260 |
Why?
|
Diagnosis, Differential | 7 | 2021 | 12974 | 0.260 |
Why?
|
Sarcoidosis | 2 | 2021 | 521 | 0.250 |
Why?
|
Education, Medical, Undergraduate | 1 | 2014 | 1070 | 0.240 |
Why?
|
Chemokine CXCL13 | 1 | 2024 | 59 | 0.230 |
Why?
|
Microstomia | 1 | 2023 | 11 | 0.230 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2023 | 32 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2024 | 286 | 0.220 |
Why?
|
Drug Therapy, Combination | 4 | 2020 | 6310 | 0.220 |
Why?
|
Drug Eruptions | 2 | 2019 | 335 | 0.220 |
Why?
|
Keloid | 1 | 2023 | 54 | 0.220 |
Why?
|
Cutis Laxa | 1 | 2023 | 29 | 0.210 |
Why?
|
Antibodies, Monoclonal | 4 | 2015 | 9177 | 0.210 |
Why?
|
Adenosine Triphosphatases | 2 | 2024 | 835 | 0.210 |
Why?
|
Internship and Residency | 3 | 2021 | 5880 | 0.210 |
Why?
|
Cicatrix, Hypertrophic | 1 | 2023 | 81 | 0.210 |
Why?
|
Immunoglobulin G | 2 | 2013 | 4544 | 0.200 |
Why?
|
Aged | 23 | 2024 | 169289 | 0.200 |
Why?
|
Ultraviolet Rays | 2 | 2020 | 1080 | 0.200 |
Why?
|
Grasshoppers | 3 | 2010 | 20 | 0.200 |
Why?
|
Dermatitis, Atopic | 2 | 2023 | 731 | 0.200 |
Why?
|
Delayed Diagnosis | 3 | 2020 | 463 | 0.200 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2024 | 220 | 0.200 |
Why?
|
Telemedicine | 2 | 2020 | 3051 | 0.200 |
Why?
|
Biopsy | 5 | 2020 | 6766 | 0.190 |
Why?
|
Curriculum | 2 | 2020 | 3743 | 0.190 |
Why?
|
Biopsy, Needle | 3 | 2016 | 1626 | 0.190 |
Why?
|
Chilblains | 1 | 2021 | 16 | 0.190 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 2021 | 22 | 0.190 |
Why?
|
Infusions, Intravenous | 2 | 2018 | 2219 | 0.190 |
Why?
|
Antipruritics | 1 | 2020 | 31 | 0.180 |
Why?
|
Lymphatic Metastasis | 3 | 2019 | 2915 | 0.180 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2020 | 10 | 0.180 |
Why?
|
Breast Neoplasms | 3 | 2020 | 21012 | 0.170 |
Why?
|
Protective Clothing | 1 | 2020 | 103 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5671 | 0.170 |
Why?
|
Acne Vulgaris | 3 | 2024 | 358 | 0.170 |
Why?
|
Face | 3 | 2020 | 1026 | 0.170 |
Why?
|
Necrobiosis Lipoidica | 1 | 2019 | 14 | 0.170 |
Why?
|
Keratoderma, Palmoplantar | 1 | 2019 | 17 | 0.160 |
Why?
|
Early Diagnosis | 2 | 2021 | 1186 | 0.160 |
Why?
|
Biological Factors | 1 | 2020 | 157 | 0.160 |
Why?
|
Anti-Inflammatory Agents | 4 | 2013 | 1809 | 0.160 |
Why?
|
Cough | 2 | 2019 | 594 | 0.160 |
Why?
|
Brachytherapy | 2 | 2017 | 1223 | 0.160 |
Why?
|
Dapsone | 2 | 2016 | 56 | 0.160 |
Why?
|
Necrosis | 1 | 2023 | 1611 | 0.160 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13380 | 0.150 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 1136 | 0.150 |
Why?
|
Patient Care Management | 1 | 2021 | 302 | 0.150 |
Why?
|
Pilot Projects | 4 | 2020 | 8631 | 0.150 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2018 | 168 | 0.150 |
Why?
|
Follow-Up Studies | 7 | 2017 | 39106 | 0.150 |
Why?
|
Sampling Studies | 2 | 2016 | 615 | 0.150 |
Why?
|
Head and Neck Neoplasms | 1 | 2012 | 2895 | 0.150 |
Why?
|
Algorithms | 2 | 2016 | 14031 | 0.150 |
Why?
|
Immunohistochemistry | 4 | 2016 | 11076 | 0.150 |
Why?
|
Chloroquine | 1 | 2019 | 274 | 0.150 |
Why?
|
Adolescent | 14 | 2024 | 88319 | 0.150 |
Why?
|
Risk Assessment | 5 | 2023 | 23995 | 0.140 |
Why?
|
Acrodermatitis | 1 | 2017 | 15 | 0.140 |
Why?
|
Comorbidity | 4 | 2021 | 10508 | 0.140 |
Why?
|
Self-Help Groups | 1 | 2019 | 192 | 0.140 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5440 | 0.140 |
Why?
|
Vasculitis | 1 | 2021 | 521 | 0.140 |
Why?
|
Cohort Studies | 11 | 2024 | 41487 | 0.140 |
Why?
|
Administration, Topical | 1 | 2019 | 704 | 0.140 |
Why?
|
Antioxidants | 2 | 2018 | 1668 | 0.140 |
Why?
|
Melanoma | 2 | 2015 | 5709 | 0.140 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4853 | 0.140 |
Why?
|
Education, Distance | 1 | 2020 | 261 | 0.140 |
Why?
|
Anti-Bacterial Agents | 1 | 2015 | 7407 | 0.140 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 26125 | 0.130 |
Why?
|
Chelating Agents | 1 | 2018 | 387 | 0.130 |
Why?
|
Lung Diseases, Interstitial | 2 | 2022 | 918 | 0.130 |
Why?
|
Erythema Nodosum | 1 | 2016 | 31 | 0.130 |
Why?
|
Diagnostic Self Evaluation | 1 | 2018 | 224 | 0.130 |
Why?
|
Arthritis | 1 | 2021 | 680 | 0.130 |
Why?
|
Th17 Cells | 1 | 2022 | 794 | 0.130 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 931 | 0.130 |
Why?
|
Drug Resistance, Multiple | 1 | 2016 | 255 | 0.120 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 4876 | 0.120 |
Why?
|
Interferon-beta | 1 | 2017 | 345 | 0.120 |
Why?
|
Dyspnea | 2 | 2019 | 1347 | 0.120 |
Why?
|
Fatal Outcome | 1 | 2019 | 1834 | 0.120 |
Why?
|
Arthralgia | 1 | 2019 | 461 | 0.120 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1386 | 0.120 |
Why?
|
Hypothyroidism | 1 | 2019 | 668 | 0.120 |
Why?
|
Retreatment | 1 | 2016 | 598 | 0.120 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6346 | 0.120 |
Why?
|
Blister | 1 | 2015 | 86 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1469 | 0.120 |
Why?
|
Child | 13 | 2024 | 80153 | 0.120 |
Why?
|
Stem Cell Transplantation | 2 | 2013 | 1600 | 0.120 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2013 | 585 | 0.120 |
Why?
|
Stroke | 1 | 2016 | 9757 | 0.110 |
Why?
|
Lichen Planus | 1 | 2014 | 70 | 0.110 |
Why?
|
Internal Medicine | 1 | 2021 | 1051 | 0.110 |
Why?
|
Drug Approval | 1 | 2021 | 814 | 0.110 |
Why?
|
Light | 1 | 2019 | 1353 | 0.110 |
Why?
|
Nails, Malformed | 1 | 2013 | 34 | 0.110 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2850 | 0.110 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2811 | 0.100 |
Why?
|
Drug Labeling | 1 | 2015 | 248 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 10766 | 0.100 |
Why?
|
Medically Underserved Area | 1 | 2015 | 254 | 0.100 |
Why?
|
Pemphigus | 1 | 2013 | 107 | 0.100 |
Why?
|
Paresthesia | 1 | 2013 | 162 | 0.100 |
Why?
|
Headache | 1 | 2020 | 1256 | 0.100 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2010 | 1250 | 0.100 |
Why?
|
Allergy and Immunology | 1 | 2014 | 176 | 0.100 |
Why?
|
Sex Factors | 4 | 2021 | 10552 | 0.100 |
Why?
|
International Cooperation | 1 | 2018 | 1422 | 0.100 |
Why?
|
United States | 8 | 2023 | 72334 | 0.100 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2024 | 4369 | 0.100 |
Why?
|
Prednisone | 2 | 2013 | 1563 | 0.090 |
Why?
|
Physicians, Women | 1 | 2017 | 508 | 0.090 |
Why?
|
Young Adult | 10 | 2024 | 59243 | 0.090 |
Why?
|
Vitellogenesis | 1 | 2010 | 3 | 0.090 |
Why?
|
Arm | 1 | 2014 | 589 | 0.090 |
Why?
|
Insect Hormones | 1 | 2010 | 73 | 0.090 |
Why?
|
Tyramine | 1 | 2010 | 53 | 0.090 |
Why?
|
Octopamine | 1 | 2010 | 43 | 0.090 |
Why?
|
Receptors, Biogenic Amine | 1 | 2010 | 4 | 0.090 |
Why?
|
Polymorphism, Genetic | 1 | 2021 | 4243 | 0.090 |
Why?
|
Naphthalenes | 1 | 2011 | 198 | 0.090 |
Why?
|
Parotid Neoplasms | 1 | 2012 | 157 | 0.090 |
Why?
|
Confidence Intervals | 1 | 2016 | 2927 | 0.090 |
Why?
|
Nephrology | 1 | 2014 | 263 | 0.090 |
Why?
|
Hyaluronic Acid | 1 | 2013 | 483 | 0.090 |
Why?
|
DNA, Mitochondrial | 2 | 2006 | 865 | 0.090 |
Why?
|
DNA-Binding Proteins | 2 | 2024 | 9606 | 0.080 |
Why?
|
Medicine | 1 | 2018 | 942 | 0.080 |
Why?
|
Occupational Health | 1 | 2016 | 806 | 0.080 |
Why?
|
Life Cycle Stages | 1 | 2010 | 160 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2011 | 242 | 0.080 |
Why?
|
Tryptases | 1 | 2010 | 176 | 0.080 |
Why?
|
Faculty, Medical | 1 | 2017 | 1203 | 0.080 |
Why?
|
Disease Progression | 3 | 2023 | 13506 | 0.080 |
Why?
|
Incidence | 3 | 2016 | 21353 | 0.080 |
Why?
|
Mastocytosis, Systemic | 1 | 2010 | 103 | 0.080 |
Why?
|
Education, Medical | 1 | 2020 | 1725 | 0.080 |
Why?
|
Anti-Infective Agents | 1 | 2016 | 983 | 0.080 |
Why?
|
Cicatrix | 1 | 2014 | 798 | 0.080 |
Why?
|
Lactic Acid | 1 | 2013 | 1139 | 0.080 |
Why?
|
Reference Values | 1 | 2015 | 4920 | 0.080 |
Why?
|
Physicians, Primary Care | 1 | 2015 | 623 | 0.080 |
Why?
|
Consensus | 3 | 2024 | 3123 | 0.080 |
Why?
|
Leadership | 1 | 2017 | 1385 | 0.070 |
Why?
|
Faculty | 2 | 2022 | 384 | 0.070 |
Why?
|
Cost of Illness | 1 | 2018 | 1936 | 0.070 |
Why?
|
Rheumatology | 1 | 2014 | 615 | 0.070 |
Why?
|
Range of Motion, Articular | 1 | 2014 | 1588 | 0.070 |
Why?
|
Drug Resistance | 1 | 2013 | 1596 | 0.070 |
Why?
|
Transcription Factors | 2 | 2024 | 12128 | 0.070 |
Why?
|
Prognosis | 3 | 2019 | 29625 | 0.070 |
Why?
|
Lung | 3 | 2022 | 10000 | 0.070 |
Why?
|
Diagnostic Errors | 1 | 2014 | 1265 | 0.070 |
Why?
|
Piperazines | 1 | 2018 | 2523 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20570 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2023 | 22176 | 0.070 |
Why?
|
Muscle, Skeletal | 2 | 2020 | 4948 | 0.070 |
Why?
|
Diphosphonates | 1 | 2011 | 636 | 0.070 |
Why?
|
Pain | 1 | 2021 | 5073 | 0.070 |
Why?
|
Polymers | 1 | 2013 | 1617 | 0.070 |
Why?
|
Biological Products | 1 | 2015 | 914 | 0.070 |
Why?
|
Neurotransmitter Agents | 1 | 2010 | 665 | 0.070 |
Why?
|
Body Mass Index | 2 | 2015 | 12953 | 0.060 |
Why?
|
Pyridines | 1 | 2018 | 2875 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7827 | 0.060 |
Why?
|
Data Collection | 1 | 2015 | 3322 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36426 | 0.060 |
Why?
|
Neuropeptides | 1 | 2010 | 944 | 0.060 |
Why?
|
Breast | 1 | 2013 | 1967 | 0.060 |
Why?
|
Skin Aging | 1 | 2006 | 141 | 0.060 |
Why?
|
Philadelphia | 1 | 2024 | 266 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9646 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2373 | 0.060 |
Why?
|
Photogrammetry | 1 | 2023 | 77 | 0.060 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2023 | 136 | 0.050 |
Why?
|
Neoplasms | 2 | 2023 | 22170 | 0.050 |
Why?
|
Diarrhea | 1 | 2010 | 1318 | 0.050 |
Why?
|
Recurrence | 2 | 2013 | 8465 | 0.050 |
Why?
|
Acute Disease | 1 | 2014 | 7237 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2020 | 58976 | 0.050 |
Why?
|
Injections, Intralesional | 1 | 2023 | 280 | 0.050 |
Why?
|
Cardiology | 1 | 2014 | 1656 | 0.050 |
Why?
|
Boston | 1 | 2015 | 9326 | 0.050 |
Why?
|
Medicare | 1 | 2021 | 6770 | 0.050 |
Why?
|
Phylogeny | 1 | 2010 | 2811 | 0.050 |
Why?
|
RNA Interference | 1 | 2010 | 2831 | 0.050 |
Why?
|
Radiography, Panoramic | 1 | 2022 | 118 | 0.050 |
Why?
|
Dermatitis | 1 | 2024 | 202 | 0.050 |
Why?
|
Ointments | 1 | 2021 | 58 | 0.050 |
Why?
|
Sequence Deletion | 1 | 2006 | 1494 | 0.050 |
Why?
|
Child, Preschool | 5 | 2024 | 42230 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3889 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2010 | 2425 | 0.050 |
Why?
|
Isotretinoin | 1 | 2022 | 134 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 2 | 2013 | 3763 | 0.040 |
Why?
|
Publication Bias | 1 | 2021 | 160 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5840 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14666 | 0.040 |
Why?
|
Mutation | 3 | 2021 | 30052 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2021 | 411 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 793 | 0.040 |
Why?
|
Risk Factors | 3 | 2023 | 74206 | 0.040 |
Why?
|
Prevalence | 2 | 2014 | 15732 | 0.040 |
Why?
|
Facial Muscles | 1 | 2020 | 159 | 0.040 |
Why?
|
Antibodies, Antinuclear | 1 | 2021 | 343 | 0.040 |
Why?
|
Genetic Markers | 1 | 2006 | 2601 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8224 | 0.040 |
Why?
|
Creatine Kinase | 1 | 2021 | 685 | 0.040 |
Why?
|
Withholding Treatment | 2 | 2013 | 617 | 0.040 |
Why?
|
Chronic Disease | 1 | 2014 | 9318 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2014 | 4486 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2024 | 974 | 0.040 |
Why?
|
Epigenomics | 1 | 2024 | 943 | 0.040 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2021 | 287 | 0.040 |
Why?
|
Databases, Factual | 1 | 2014 | 7967 | 0.040 |
Why?
|
Clinical Competence | 1 | 2014 | 4792 | 0.040 |
Why?
|
Back | 1 | 2018 | 64 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1152 | 0.040 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2022 | 474 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2022 | 644 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 706 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2015 | 10194 | 0.040 |
Why?
|
Obesity | 1 | 2019 | 12947 | 0.030 |
Why?
|
Infant | 2 | 2020 | 36192 | 0.030 |
Why?
|
PUVA Therapy | 1 | 2016 | 101 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6485 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15266 | 0.030 |
Why?
|
Chemokine CXCL10 | 1 | 2017 | 316 | 0.030 |
Why?
|
Thyroid Diseases | 1 | 2019 | 386 | 0.030 |
Why?
|
Schools, Medical | 1 | 2022 | 879 | 0.030 |
Why?
|
Deglutition Disorders | 1 | 2021 | 625 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2017 | 882 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13639 | 0.030 |
Why?
|
Delphi Technique | 1 | 2018 | 846 | 0.030 |
Why?
|
Thorax | 1 | 2018 | 555 | 0.030 |
Why?
|
North America | 1 | 2017 | 1276 | 0.030 |
Why?
|
Depression | 2 | 2023 | 8124 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2281 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 9280 | 0.030 |
Why?
|
Age Distribution | 1 | 2019 | 2880 | 0.030 |
Why?
|
Income | 1 | 2022 | 1877 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4575 | 0.030 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2013 | 85 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9420 | 0.030 |
Why?
|
Urticaria | 1 | 2013 | 150 | 0.030 |
Why?
|
Students | 1 | 2022 | 1741 | 0.020 |
Why?
|
Polyesters | 1 | 2013 | 373 | 0.020 |
Why?
|
Extremities | 1 | 2017 | 867 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2019 | 868 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 11742 | 0.020 |
Why?
|
Mitochondria | 1 | 2004 | 3624 | 0.020 |
Why?
|
Qualitative Research | 1 | 2022 | 3023 | 0.020 |
Why?
|
Citalopram | 1 | 2013 | 402 | 0.020 |
Why?
|
Europe | 1 | 2017 | 3422 | 0.020 |
Why?
|
Ranitidine | 1 | 2010 | 34 | 0.020 |
Why?
|
Folic Acid | 1 | 2017 | 1323 | 0.020 |
Why?
|
Flushing | 1 | 2010 | 52 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 694 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4063 | 0.020 |
Why?
|
Cromolyn Sodium | 1 | 2010 | 78 | 0.020 |
Why?
|
Leukotriene Antagonists | 1 | 2010 | 124 | 0.020 |
Why?
|
Radiotherapy | 1 | 2016 | 1499 | 0.020 |
Why?
|
Behcet Syndrome | 1 | 2010 | 86 | 0.020 |
Why?
|
Insurance, Health | 1 | 2022 | 2498 | 0.020 |
Why?
|
Sulfides | 1 | 2010 | 169 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2022 | 3461 | 0.020 |
Why?
|
Staurosporine | 1 | 2010 | 242 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3201 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9610 | 0.020 |
Why?
|
Histamine H2 Antagonists | 1 | 2010 | 166 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3305 | 0.020 |
Why?
|
Alcoholism | 1 | 2019 | 1973 | 0.020 |
Why?
|
Acetates | 1 | 2010 | 321 | 0.020 |
Why?
|
Cyclopropanes | 1 | 2010 | 432 | 0.020 |
Why?
|
Atrophy | 1 | 2013 | 1633 | 0.020 |
Why?
|
Crohn Disease | 2 | 2011 | 2279 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8830 | 0.020 |
Why?
|
Students, Medical | 1 | 2020 | 1936 | 0.020 |
Why?
|
Vomiting | 1 | 2010 | 651 | 0.020 |
Why?
|
Plasma Cells | 1 | 2010 | 599 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1664 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2024 | 11528 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54425 | 0.020 |
Why?
|
Species Specificity | 1 | 2010 | 2414 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12725 | 0.020 |
Why?
|
DNA Primers | 1 | 2010 | 2819 | 0.020 |
Why?
|
Eosinophils | 1 | 2010 | 950 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20098 | 0.020 |
Why?
|
Heteroduplex Analysis | 1 | 2004 | 9 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4652 | 0.020 |
Why?
|
Electrophoresis, Capillary | 1 | 2004 | 63 | 0.020 |
Why?
|
Quinolines | 1 | 2010 | 764 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2010 | 4174 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18395 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2013 | 2161 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2014 | 2093 | 0.010 |
Why?
|
Central Nervous System | 1 | 2010 | 1336 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5146 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2017 | 12795 | 0.010 |
Why?
|
Overweight | 1 | 2012 | 2417 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8654 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 3712 | 0.010 |
Why?
|
Physicians | 1 | 2017 | 4591 | 0.010 |
Why?
|
Hypertension | 1 | 2019 | 8540 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2014 | 4026 | 0.010 |
Why?
|
Animals | 3 | 2010 | 168459 | 0.010 |
Why?
|
Base Sequence | 1 | 2004 | 12441 | 0.010 |
Why?
|
Genome, Human | 1 | 2004 | 4425 | 0.010 |
Why?
|